Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts
Peter Martin(Northwestern University), Gilles Salles(Memorial Sloan Kettering Cancer Center), Jonathon B. Cohen(Emory University), Kami J. Maddocks(The Ohio State University), K. Daly(Janssen (United States)), Jeffrey M. Switchenko(Emory University), Diego Villa(BC Cancer Agency), Keqin Qi(Janssen (United States)), Brad S. Kahl(UW Health University Hospital), Natalie S. Grover(University of North Carolina at Chapel Hill), Anita Kumar(Memorial Sloan Kettering Cancer Center), Michael Wang(St. Joseph Health System), Lori Parisi(Janssen (United States)), Angeline Zhu(Janssen (United States)), Brian T. Hill(Cleveland Clinic)
Cited by 82
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k